Quick Facts

• May help with the symptomatic management of pain and inflammation.
• Used for inflammatory and degenerative rheumatic conditions.
• May be utilized for conditions such as rheumatoid arthritis and osteoarthritis.
• Contributes to relief for painful spinal syndromes and soft-tissue rheumatism.

---

Fenil-V Retard is a prescribed medication intended for the symptomatic management of pain and inflammation associated with a range of conditions. Its established uses include addressing the manifestations of inflammatory and degenerative forms of rheumatism, such as rheumatoid arthritis and osteoarthritis. The drug may contribute to relief from discomfort associated with painful syndromes affecting the spinal column, including sciatica and lumbago.

Furthermore, this medication is a therapeutic option for addressing soft-tissue rheumatism and is sometimes utilized for the management of primary dysmenorrhea. It is also indicated for the temporary management of acute episodes of gout and for addressing post-traumatic inflammation and swelling. Healthcare providers determine appropriate use based on individual patient needs and the nature of the condition.

The medication's role is to aid in controlling symptoms and improving mobility where pain and inflammation are factors.

Regulatory References

1. EMA therapeutic overview

Fenil-V Retard (Diclofenac Extended-Release) eligibility is determined by strict rules outlined in official regulatory documents. Use is primarily restricted to adults (18 years and older), as its safety and efficacy are not established in the pediatric population. Elderly patients require particular caution.

Contraindicated Populations

Official labeling mandates that the medicine must not be used by patients with:

• Known allergy to diclofenac, aspirin, or any other NSAID.
• Active gastrointestinal (GI) ulcer, bleeding, or perforation, or a history of recurrent GI bleeding.
• Established Congestive Heart Failure (NYHA Class II–IV), Ischaemic Heart Disease, Peripheral Arterial Disease, and/or Cerebrovascular Disease.
• Severe hepatic failure or severe renal failure.
• Perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• The last trimester of pregnancy (after 30 weeks gestation).

Restricted and Conditional Use

Use is not recommended while breastfeeding or for women attempting to conceive. Caution is required in patients with mild-to-moderate renal or hepatic impairment, a history of hypertension, or certain inflammatory bowel conditions (e.g., Ulcerative Colitis).

The active substance in Fenil-V Retard, Diclofenac, is known to interact with several other medicinal products and substances, resulting in officially documented risk classifications and restrictions.

Interaction Classifications and Risk

Classification	Interacting Substance/Class	Official Interaction Pattern
Pharmacokinetic	Voriconazole (CYP2C9 inhibitor)	Significantly increases Diclofenac's systemic exposure (Cmax and AUC) due to reduced metabolic clearance.
	Lithium, Digoxin	Increases the plasma concentration and prolongs the half-life of these co-administered drugs by reducing their renal clearance.
Pharmacodynamic	Oral Anticoagulants (e.g., Warfarin), SSRIs/SNRIs	Increases the risk of serious bleeding events due to additive effects on blood clotting.
	ACE Inhibitors, Diuretics	Reduces the blood pressure-lowering or fluid-eliminating effects and may lead to deterioration of kidney function.

Official Use Restrictions

Co-administration with other NSAIDs, including analgesic doses of Aspirin, is generally not recommended due to an amplified risk of serious gastrointestinal adverse events. Use is formally contraindicated in the treatment of peri-operative pain for patients undergoing Coronary Artery Bypass Graft (CABG) surgery. Additionally, consumption of alcohol is documented to increase the risk of serious gastrointestinal problems, including ulcers and bleeding. Patients who are elderly, volume-depleted, or have underlying renal impairment are noted in regulatory labels to be at higher risk for severe kidney function deterioration when co-administering with ACE Inhibitors or ARBs.

Core Mechanism: Cyclooxygenase Enzyme Inhibition

Fenil-V Retard, containing Diclofenac, acts as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically engaging both COX-1 and COX-2. This molecular interaction blocks the catalytic conversion of arachidonic acid into prostaglandins, which are powerful lipid signaling molecules. This blockade initiates the primary mechanistic cascade, resulting in a decreased biosynthesis of eicosanoids at the cellular level.

System-Level Physiological Modulation

This reduction in prostaglandins modulates the excitability of peripheral sensory neurons (nociception) and influences the thermoregulatory set point within the hypothalamus (thermoregulation). The drug's sustained-release (Retard) formulation ensures prolonged modulation of the lipid signaling system, facilitating a sustained decrease in eicosanoid mediators over an extended time course. This action ultimately shapes the pharmacodynamic profile of the compound.

The usage of Fenil-V Retard (Diclofenac 100 mg Extended-Release) is strictly governed by its specialized formulation, requiring adherence to official administration guidelines.

Administration Scope

Feature	Official Labeled Instruction
Route of Administration	Oral route only.
Standard Dosing Schedule	The standard regimen is 100 mg, taken as a single tablet. Some instructions may permit a maximum daily dose up to 200 mg for specific conditions under strict medical supervision.
Timing in Relation to Meals	The tablet is advised to be taken with liquid, preferably with or after food. Food intake will delay the time to achieve peak concentration, but does not substantially affect the overall absorption of the active ingredient.
Age-Group Rules	The 100 mg extended-release tablet is not suitable for children. Dose adjustment is typically not necessary for patients with mild to moderate renal dysfunction.
Special Procedural Conditions	The tablet must be swallowed whole. It must not be cut, crushed, or chewed to preserve the integrity of the prolonged-release mechanism.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration Method Type	Oral
Frequency Pattern	Once daily
Regulatory Basis	Governed by established pharmaceutical and clinical principles.
Use-Context Constraints	The fundamental principle is the mandate to always use the lowest effective dose for the shortest possible duration of therapy.

Resulting Procedural Structure

The official instructions establish a standardized, non-variable method of administration. The single once-daily dose and the necessity to swallow the extended-release tablet whole define the core protocol for its use. This procedural structure is necessary to ensure the consistent, prolonged release of the active ingredient, as intended by the formulation.

Fenil-V Retard: Research Evidence Overview

Fenil-V Retard was studied for research exploring symptom patterns across a range of conditions. The information presented here describes the structure of the research that contributes to the evidence base for the medicine's approved uses, focusing on the types of trials conducted, the outcomes measured, and areas where evidence is limited or data are still emerging.

---

Evidence for Use in Chronic Inflammatory and Degenerative Conditions

The evidence base for conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis primarily relies on Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were evaluated in adults and older adults with functional limitations. Researchers examined outcomes related to physical discomfort and daily functioning, comparing the active ingredient against placebo or other treatment classes. Research describes patterns related to outcomes linked to inflammatory states. A significant portion of this evidence was studied for the overall drug class, rather than the extended-release formulation alone.

---

Evidence for Use in Acute Pain and Time-Limited Conditions

Research for acute situations, such as primary dysmenorrhea and acute gout, consists of short-term RCTs that were observed in adults experiencing temporary, intense symptoms. Studies explored acute changes by examining how quickly outcomes related to physical discomfort shifted and by monitoring the need for additional pain relief medication. However, evidence is limited because many high-quality acute pain studies used immediate-release versions of the drug, meaning subgroup findings are uncertain for some specific acute uses of this extended-release formulation.

---

Long-Term Studies and Observation Periods

The drug was studied for outcomes related to long-term symptom patterns. Initial efficacy trials often had limited follow-up, but the evidence base includes programs where patients were observed over intermediate and long-term observation periods. This long-term research contributes to the broader evidence landscape regarding continuous use. Specific data on long-term functional outcomes are often limited to the drug class rather than focused solely on the extended-release form.

---

Research in Specific Patient Groups

Studies were evaluated in certain specific patient groups, including older adults with inflammatory conditions. Research examined cohorts where physiological response was studied for differences compared to the general adult population. For other specific groups, such as children, women who are pregnant or breastfeeding, and those with certain pre-existing comorbidities, data are still emerging or the available research is limited.

---

The Landscape of Evidence Gaps and Uncertainties

Despite the substantial body of evidence, certain areas remain uncertain regarding this specific extended-release formulation. A key limitation is that comparative evidence against all available treatment options is lacking in the published literature. Furthermore, data for certain groups remain insufficient, and long-term effects are not fully established for all possible patient-specific outcomes. The research provides context but not individual predictions.

Key Studies & References

1. Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain (Long-term open-label safety study NCT01510912)
2. Safety, pharmacokinetics, and preliminary pharmacodynamics of 1% and 3% diclofenac vaginal hydrogel for the treatment of primary dysmenorrhea (Study referencing acute pain use of immediate-release forms, NCT05752526)

Common questions about Fenil-V Retard (FAQ)

Q: Can Fenil-V Retard be taken for short-term pain relief?

A: Official regulatory guidelines emphasize that the lowest effective dose should be used for the shortest possible duration of therapy. This principle indicates that the use of Fenil-V Retard for managing acute, time-limited pain and inflammation is consistent with regulatory guidance.

Q: Is Fenil-V Retard a treatment for chronic conditions or acute flare-ups?

A: Fenil-V Retard is officially indicated for the management of signs and symptoms associated with both chronic conditions and acute pain events. This includes chronic inflammatory conditions such as rheumatoid arthritis, as well as acute issues like painful menstruation (primary dysmenorrhea) and acute flares of gout.

Q: Is it normal to feel a bit dizzy or drowsy after taking Fenil-V Retard?

A: Official product information documents that feeling dizzy or having a headache is a common side effect of the medicine. Somnolence, which means drowsiness or feeling sleepy, is also listed as a known but rare side effect. Because these effects are noted in the label, caution regarding activities like driving may be necessary.

Q: Does Fenil-V Retard contain any addictive substances?

A: No. Fenil-V Retard's active ingredient, Diclofenac, is a Nonsteroidal Anti-inflammatory Drug (NSAID). According to regulatory classifications by government bodies, NSAIDs are not scheduled as controlled substances or narcotics and are not considered to have addictive properties.

Q: Can Fenil-V Retard cause an allergic reaction, and what are the signs?

A: Yes, regulatory documents list hypersensitivity reactions, which are allergic responses, as possible serious adverse effects. Signs can include difficulty breathing, skin rash, or angioedema (swelling of the face, tongue, or throat). Regulatory warnings specify that these severe reactions may occur.

Q: Can Fenil-V Retard cause water retention or swelling?

A: Official safety information notes that fluid retention and edema (swelling) have been reported during treatment with NSAID medications, including this one. Official information indicates that caution is necessary, particularly for individuals with pre-existing heart conditions.

Q: Can Fenil-V Retard affect the results of any medical tests?

A: Yes. Regulatory labeling indicates that the use of Fenil-V Retard is commonly associated with an increase in liver enzyme values (transaminases). For individuals undergoing long-term use, regulatory guidance suggests that monitoring of liver function may be clinically indicated.

Q: Is Fenil-V Retard considered a prescription-only medicine?

A: Yes. The active ingredient in this prolonged-release formulation is classified by regulatory authorities as a prescription-only medicine. This means it can only be obtained with a valid prescription from a licensed healthcare provider.

Q: Can Fenil-V Retard be used for menstrual pain?

A: Yes, the medication is formally indicated for the relief of the signs and symptoms of primary dysmenorrhea, which is the medical term for painful menstruation. This is one of its approved uses according to official prescribing information.

Q: Are there any specific dietary considerations when taking Fenil-V Retard?

A: Official documents advise that the tablets should be taken with liquid and preferably with or after food. Additionally, if the medication contains specific inactive ingredients like sucrose, regulatory information notes that individuals with conditions like hereditary fructose intolerance may need to avoid its use.

Q: Is it normal for Fenil-V Retard to cause ringing in the ears (tinnitus)?

A: While not common, tinnitus (a ringing or buzzing in the ears) is listed as a very rare adverse reaction in regulatory safety documents for this drug class. This effect is a documented potential side effect.

Q: Can Fenil-V Retard affect fertility?

A: Yes. Official information states that the use of Diclofenac and other anti-inflammatory medicines may potentially impair female fertility temporarily. For this reason, regulatory documents state that it is generally not recommended for women who are actively attempting to conceive.

Q: Are there any known long-term effects of taking Fenil-V Retard?

A: Yes, official warnings exist regarding use over an extended period. Regulatory documents state that the risk of serious cardiovascular thrombotic events (such as heart attack or stroke) increases with the duration of use, which is a key long-term safety concern for this drug class.

Q: Does taking antacids interfere with how Fenil-V Retard is absorbed?

A: Official interaction data suggests that the co-administration of antacids may diminish the maximum concentrations of the active component in the blood. This means that the full absorption peak of the medicine might not be achieved if taken simultaneously with antacids.

Q: What is the purpose of the enteric coating (if applicable) on Fenil-V Retard tablets?

A: The tablets often have an enteric-coating, which is a special covering. This coating is intended to prevent the drug from dissolving in the stomach, which is one measure taken to minimize the potential for local gastrointestinal irritation.

Q: Can Fenil-V Retard be used for headaches or migraines?

A: While immediate-release forms of Diclofenac are sometimes indicated for the acute treatment of migraines, the extended-release (Retard) formulation is generally not indicated for this acute type of pain. Its prolonged action is more suited for sustained inflammatory conditions.

Q: How does the prolonged-release (Retard) formulation help with conditions like arthritis?

A: The prolonged-release feature is engineered to release the Diclofenac gradually over an extended period. This mechanism ensures sustained therapeutic concentrations of the medicine in the body, which helps to consistently manage the persistent discomfort and inflammation associated with chronic conditions like arthritis.

How to Store and Dispose of Fenil-V Retard?

The storage and disposal of Fenil-V Retard (Diclofenac Sodium extended-release tablets) must strictly adhere to regulatory requirements to ensure product stability and safety.

---

Storage Requirements

The medicine must be kept at a temperature not exceeding 25°C. It is mandatory to store the tablets in their original container to protect from moisture.

• Child Safety: It must be kept out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Instructions

Unused or expired Fenil-V Retard must be disposed of in accordance with local requirements. Official labeling instructs not to throw the medicine into wastewater or household waste, requiring proper pharmaceutical waste handling.